Dr. Ted W. Love, former President & CEO of Global Blood Therapeutics (GBT) and is currently Chair of the Board of Directors of the Biotechnology Industry Association (BIO). Prior to GBT, Dr. Love served as executive vice president, research and development and technical operations at Onyx Pharmaceuticals, where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, he served as president, chief executive officer and chairman of Nuvelo, where he led growth of the company to a market capitalization of $1 billion. Prior to that, Dr. Love served as senior vice president, development, at Theravance.

Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as chairman of Genentech’s Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva® and Avastin®. Dr. Love served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital.

Dr. Love is a distinguished industry leader with more than two decades of management experience in the biopharmaceutical industry, along with nearly a decade of prior experience as a practicing physician. He has spent much of his career focused on addressing the ongoing healthcare disparities facing the sickle cell disease community and leading the development of therapies for this underserved patient population.

Dr. Love currently serves on the boards of directors of Royalty Pharma and Seagen. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.